Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Thoracic 2Dermatologic 2Breast 2NET 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

Fluorodeoxyglucose F18 2tivozanib 1tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1regorafenib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lactones 1Irinotecan 1Interleukin-2 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Interleukin-2 × NET × Clear all
NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
51 enrolled
EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡